GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » 10-Year ROIIC %

HLTRF (HLS Therapeutics) 10-Year ROIIC % : -10.77% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. HLS Therapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was -10.77%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for HLS Therapeutics's 10-Year ROIIC % or its related term are showing as below:

HLTRF's 10-Year ROIIC % is ranked worse than
74.25% of 932 companies
in the Drug Manufacturers industry
Industry Median: 3.685 vs HLTRF: -10.77

HLS Therapeutics 10-Year ROIIC % Historical Data

The historical data trend for HLS Therapeutics's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics 10-Year ROIIC % Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.70 -5.91 -7.17 -12.50 -10.77

HLS Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -10.77 - - -

Competitive Comparison of HLS Therapeutics's 10-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's 10-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's 10-Year ROIIC % falls into.



HLS Therapeutics 10-Year ROIIC % Calculation

HLS Therapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -10.2475798 (Dec. 2023) - 9.469284 (Dec. 2013) )/( 177.265 (Dec. 2023) - 15.708 (Dec. 2013) )
=-19.7168638/161.557
=-12.20%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


HLS Therapeutics  (OTCPK:HLTRF) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


HLS Therapeutics 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.